CA2340636A1 - Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents - Google Patents
Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents Download PDFInfo
- Publication number
- CA2340636A1 CA2340636A1 CA002340636A CA2340636A CA2340636A1 CA 2340636 A1 CA2340636 A1 CA 2340636A1 CA 002340636 A CA002340636 A CA 002340636A CA 2340636 A CA2340636 A CA 2340636A CA 2340636 A1 CA2340636 A1 CA 2340636A1
- Authority
- CA
- Canada
- Prior art keywords
- 3alkyl
- ring
- represents hydrogen
- specific phosphodiesterase
- combinations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
Abstract
A compound of formula (I) and salts and solvates thereof, in which: R0 represents hydrogen, halogen, or C1-6alkyl; R1 represents hydrogen, C1-6-alkyl, C2-6alkenyl, C2-6alkynyl, haloC1-6alkyl, C3-8cycloalkyl, C3-8cyloalkylC1-3alkyl, arylC1-3alkyl, or heteroarylC1-3alkyl; R2 represents an optionally substituted monocyclic aromatic ring selected from benzene, thiophene, furan, and pyridine, or an optionally substituted bicyclic ring (a) attached to the rest of the molecule via one of the benzene ring carbon atoms, and wherein the fused ring (A) is a 5- or 6-membered ring which may be saturated or partially or fully unsaturated, and comprises carbon atoms and optionally one or two heteroatoms selected from oxygen, sulphur, and nitrogen;
and R3 represents hydrogen or C1-3alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders and erectile dysfunction.
and R3 represents hydrogen or C1-3alkyl, or R1 and R3 together represent a 3- or 4-membered alkyl or alkenyl chain. A compound of formula (I) is a potent and selective inhibitor of cyclic guanosine 3', 5'-monophosphate specific phosphodiesterase (cGMP specific PDE) having a utility in a variety of therapeutic areas where such inhibition is beneficial, including the treatment of cardiovascular disorders and erectile dysfunction.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/154,051 US6143746A (en) | 1994-01-21 | 1998-09-16 | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US09/154,051 | 1998-09-16 | ||
PCT/US1999/019466 WO2000015228A1 (en) | 1998-09-16 | 1999-08-26 | Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2340636A1 true CA2340636A1 (en) | 2000-03-23 |
CA2340636C CA2340636C (en) | 2007-08-07 |
Family
ID=22549790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002340636A Expired - Fee Related CA2340636C (en) | 1998-09-16 | 1999-08-26 | Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents |
Country Status (7)
Country | Link |
---|---|
US (1) | US6143746A (en) |
EP (3) | EP2327408A1 (en) |
JP (1) | JP2002524516A (en) |
AU (1) | AU5785699A (en) |
BR (1) | BR9913824A (en) |
CA (1) | CA2340636C (en) |
WO (1) | WO2000015228A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018188446A1 (en) * | 2017-04-14 | 2018-10-18 | 中山大学 | Evodiamine compounds, preparation method therefor and application thereof |
Families Citing this family (58)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20060222647A1 (en) * | 1993-05-27 | 2006-10-05 | Beavo Joseph A | Methods and compositions for modulating the activity of PDE5 |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US6331543B1 (en) | 1996-11-01 | 2001-12-18 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use |
DK1049695T3 (en) * | 1997-11-12 | 2002-05-13 | Bayer Ag | 2-Phenyl-substituted imidazotriazinones as phosphodiesterase inhibitors |
GB9801398D0 (en) | 1998-01-22 | 1998-03-18 | Anggard Erik E | Chemical compounds |
CZ20021151A3 (en) | 1999-10-11 | 2003-03-12 | Pfizer Inc. | 5-(2-substituted-5-heterocyclyl sulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ones functioning as phosphodiesterase inhibitors |
IL139456A0 (en) | 1999-11-08 | 2001-11-25 | Pfizer | Compounds for the treatment of female sexual dysfunction |
US20020013327A1 (en) * | 2000-04-18 | 2002-01-31 | Lee Andrew G. | Compositions and methods for treating female sexual dysfunction |
CN1630532A (en) * | 2000-04-19 | 2005-06-22 | 约翰斯霍普金斯大学 | Methods for prevention and treatment of gastrointestinal disorders |
WO2001094347A1 (en) * | 2000-06-08 | 2001-12-13 | Lilly Icos Llc | Tetracyclic diketopiperazine compounds as pdev inhibitors |
ATE300543T1 (en) * | 2000-06-26 | 2005-08-15 | Lilly Icos Llc | CONDENSED PYRAZINEDIONE DERIVATIVES AS PDE5 INHIBITERS |
US6503894B1 (en) | 2000-08-30 | 2003-01-07 | Unimed Pharmaceuticals, Inc. | Pharmaceutical composition and method for treating hypogonadism |
US6821978B2 (en) * | 2000-09-19 | 2004-11-23 | Schering Corporation | Xanthine phosphodiesterase V inhibitors |
DE10058663A1 (en) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Use of thienopyrimidines |
CA2431074A1 (en) * | 2000-12-19 | 2002-06-27 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Pharmaceutical formulation comprising thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (1) |
EP1347762A2 (en) * | 2000-12-19 | 2003-10-01 | MERCK PATENT GmbH | Pharmaceutical formulation containing thienopyrimidines and antithrombotics, calcium antagonists, prostaglandins or prostaglandin derivatives (2) |
SK8192003A3 (en) * | 2000-12-19 | 2003-10-07 | Merck Patent Gmbh | Pharmaceutical formulation containing pyrazolo[4,3-d]pyrimidines and antithrombotic agents, calcium-antagonists, prostaglandins or prostaglandin derivatives |
EP1392314B1 (en) * | 2001-05-09 | 2006-12-20 | Bayer HealthCare AG | NOVEL USE OF 2-[2-Ethoxy-5-(4-methyl-piperazin-1-sulfonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-on |
US20070122353A1 (en) | 2001-05-24 | 2007-05-31 | Hale Ron L | Drug condensation aerosols and kits |
US7458374B2 (en) | 2002-05-13 | 2008-12-02 | Alexza Pharmaceuticals, Inc. | Method and apparatus for vaporizing a compound |
US7645442B2 (en) | 2001-05-24 | 2010-01-12 | Alexza Pharmaceuticals, Inc. | Rapid-heating drug delivery article and method of use |
US7766013B2 (en) | 2001-06-05 | 2010-08-03 | Alexza Pharmaceuticals, Inc. | Aerosol generating method and device |
MXPA03011167A (en) * | 2001-06-21 | 2004-02-26 | Lilly Icos Llc | Carboline derivatives as pdev inhibitors. |
DE10135815A1 (en) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain |
WO2003013432A2 (en) * | 2001-08-10 | 2003-02-20 | Nitromed, Inc. | Methods of use for novel sulfur containing organic nitrate compounds |
US6479493B1 (en) | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
EP1442042A1 (en) * | 2001-11-09 | 2004-08-04 | Schering Corporation | Polycyclic guanine derivative phosphodiesterase v inhibitors |
US6686349B2 (en) | 2001-11-14 | 2004-02-03 | Ortho-Mcneil Pharmaceutical, Inc. | Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors |
CA2469075C (en) * | 2001-12-20 | 2011-09-13 | Applied Research Systems Ars Holding N.V. | Pyrrolidine derivatives as prostaglandin modulators |
US20030216407A1 (en) * | 2002-01-31 | 2003-11-20 | Pfizer Inc. | Use of PDE5 inhibitors in the treatment of scarring |
JP2005529927A (en) * | 2002-05-23 | 2005-10-06 | ファイザー インコーポレイテッド | New combination |
DE10232113A1 (en) * | 2002-07-16 | 2004-01-29 | Bayer Ag | Medicinal products containing vardenafil hydrochloride trihydrate |
US6531162B1 (en) * | 2002-07-30 | 2003-03-11 | William Charles Llewellyn | Adrenergically-mediated weight loss product |
US8133903B2 (en) * | 2003-10-21 | 2012-03-13 | Los Angeles Biomedical Research Institute at Harbor—UCLA Medical Center | Methods of use of inhibitors of phosphodiesterases and modulators of nitric oxide, reactive oxygen species, and metalloproteinases in the treatment of peyronie's disease, arteriosclerosis and other fibrotic diseases |
US20040105818A1 (en) | 2002-11-26 | 2004-06-03 | Alexza Molecular Delivery Corporation | Diuretic aerosols and methods of making and using them |
US7913688B2 (en) | 2002-11-27 | 2011-03-29 | Alexza Pharmaceuticals, Inc. | Inhalation device for producing a drug aerosol |
KR20070091049A (en) | 2002-12-13 | 2007-09-06 | 워너-램버트 캄파니 엘엘씨 | Alpha-2-delta ligand to treat lower urinary tract symptoms |
US20050048573A1 (en) * | 2003-02-03 | 2005-03-03 | Plexxikon, Inc. | PDE5A crystal structure and uses |
WO2005079808A1 (en) | 2004-01-22 | 2005-09-01 | Pfizer Limited | Triazole derivatives which inhibit vasopressin antagonistic activity |
EP1742932A1 (en) * | 2004-04-28 | 2007-01-17 | Pfizer Limited | 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor |
DE102004023069A1 (en) * | 2004-05-11 | 2005-12-08 | Bayer Healthcare Ag | New dosage forms of the PDE 5 inhibitor vardenafil |
US20060083724A1 (en) * | 2004-10-01 | 2006-04-20 | Hilst Todd W | Compositions for the treatment of femal sexual dysfunction |
DE102005001989A1 (en) * | 2005-01-15 | 2006-07-20 | Bayer Healthcare Ag | Intravenous formulations of PDE inhibitors |
DE102005009240A1 (en) * | 2005-03-01 | 2006-09-07 | Bayer Healthcare Ag | Dosage forms with improved pharmacokinetic properties |
WO2007016361A2 (en) | 2005-07-29 | 2007-02-08 | Concert Pharmaceuticals Inc. | Novel pharmaceutical compounds |
BRPI0616633A2 (en) * | 2005-09-29 | 2011-06-28 | Bayer Healthcare Ag | pde inhibitors and combinations thereof for the treatment of urological disorders |
DK1937276T3 (en) | 2005-10-12 | 2013-02-11 | Besins Healthcare Luxembourg | IMPROVED TESTOSTERONGEL AND PROCEDURE TO USE THEREOF |
US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
WO2008103470A2 (en) * | 2007-02-21 | 2008-08-28 | Trustees Of Columbia University In The City Of New York | Oncogenic-ras-signal dependent lethal compounds |
US20080216828A1 (en) | 2007-03-09 | 2008-09-11 | Alexza Pharmaceuticals, Inc. | Heating unit for use in a drug delivery device |
FR2916200A1 (en) * | 2007-05-18 | 2008-11-21 | Fourtillan Snc | New 1,2,3,4,6,7,12,12a-octahydro-pyrazino(1',2':1,6)pyrido(3,4-b)indole compounds are 5-hydroxy tryptamine-2 receptor antagonist useful to treat e.g. depression, anxiety, Parkinson's disease, Alzheimer's disease and cancer |
CA2689638A1 (en) * | 2007-06-13 | 2008-12-18 | Bayer Schering Pharma Aktiengesellschaft | Pde inhibitors for the treatment of hearing impairment |
EP2181997A1 (en) * | 2008-10-30 | 2010-05-05 | Chemo Ibérica, S.A. | A process for the preparation of tadalafil |
US9023890B2 (en) * | 2009-12-02 | 2015-05-05 | The Charlotte-Mecklenburg Hospital Authority | Nitrate esters and their use for the treatment of muscle and muscle related diseases |
US9452117B2 (en) | 2011-06-01 | 2016-09-27 | The Charlotte-Mecklenburg Hospital Authority | Nitrate esters and their use for the treatment of muscle and muscle related diseases |
CN104086546B (en) * | 2014-07-14 | 2016-08-17 | 福建广生堂药业股份有限公司 | Medicinal hydrochlorate of tadanafil and preparation method thereof |
WO2017168174A1 (en) | 2016-04-02 | 2017-10-05 | N4 Pharma Uk Limited | New pharmaceutical forms of sildenafil |
CN106810554B (en) * | 2017-01-14 | 2019-02-15 | 山东罗欣药业集团恒欣药业有限公司 | A kind of preparation method of Tadalafei compound |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3644384A (en) * | 1969-06-09 | 1972-02-22 | Sterling Drug Inc | Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives |
US3717638A (en) * | 1971-03-11 | 1973-02-20 | Sterling Drug Inc | 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR |
US3917599A (en) * | 1973-03-30 | 1975-11-04 | Council Scient Ind Res | 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles |
GB1454171A (en) * | 1973-10-19 | 1976-10-27 | Council Scient Ind Res | Tetracyclic compounds |
US4188390A (en) * | 1977-11-05 | 1980-02-12 | Pfizer Inc. | Antihypertensive 4-amino-2-[4-(1,4-benzodioxan-2-carbonyl) piperazin-1-yl or homopiperazin-1-yl]quinazolines |
GR79603B (en) * | 1982-07-24 | 1984-10-31 | Pfizer | |
US4801587A (en) * | 1987-03-02 | 1989-01-31 | Gene Voss | Impotence ointment |
IT1217190B (en) * | 1988-04-22 | 1990-03-14 | Recordati Chem Pharm | USEFUL COMPOUNDS FOR THE TREATMENT AND DIAGNOSIS OF HURRY DYSFUNCTIONS |
EP0357122A3 (en) * | 1988-08-29 | 1991-10-23 | Duphar International Research B.V | Use of beta-carbolines, their bio-isosteric benzofuran and benzothiophene analogues for the manufacture of a medicament having cytostatic properties |
DE3830096A1 (en) * | 1988-09-03 | 1990-03-15 | Hoechst Ag | PIPERAZINDIONE WITH PSYCHOTROPER EFFECT |
FR2649613B1 (en) * | 1989-07-11 | 1991-09-27 | Virag Ronald | VASO-ACTIVE MEDICINE |
JPH0344324A (en) * | 1989-07-13 | 1991-02-26 | Kazuoki Tsuchiya | Sexual function invigorator |
US5270323A (en) * | 1990-05-31 | 1993-12-14 | Pfizer Inc. | Method of treating impotence |
DE69105040T2 (en) * | 1990-05-31 | 1995-03-23 | Pfizer | Medicines for impotence. |
GB9013750D0 (en) * | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
US5399581A (en) * | 1990-12-26 | 1995-03-21 | Laragh; John H. | Method and compositions for treatment of sexual impotence |
GB9114760D0 (en) * | 1991-07-09 | 1991-08-28 | Pfizer Ltd | Therapeutic agents |
DE4220264A1 (en) * | 1992-06-20 | 1993-12-23 | Cassella Ag | Phenyl-1,2,5-oxadiazole-carbonamide-2-oxide |
US5646181A (en) * | 1992-07-02 | 1997-07-08 | Research Foundation Of State University Of New York | Method and compositions for treating impotence |
GB9218322D0 (en) * | 1992-08-28 | 1992-10-14 | Pfizer Ltd | Therapeutic agents |
EP0611248B1 (en) * | 1993-02-10 | 2000-03-22 | B.M.R.A. Corporation B.V. | Pharmaceutical composition for treating impotence containing an alpha-1-inhibitor and an alpha-2 inhibitor |
US5698589A (en) * | 1993-06-01 | 1997-12-16 | International Medical Innovations, Inc. | Water-based topical cream containing nitroglycerin and method of preparation and use thereof |
GB9301192D0 (en) * | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
US5565466A (en) * | 1993-08-13 | 1996-10-15 | Zonagen, Inc. | Methods for modulating the human sexual response |
CN1060042C (en) * | 1993-10-27 | 2001-01-03 | 法玛西雅厄普约翰美国公司 | Stabilized prostaglandin E 1 |
GB9514465D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Chemical compounds |
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
GB9401090D0 (en) * | 1994-01-21 | 1994-03-16 | Glaxo Lab Sa | Chemical compounds |
DE69514794T2 (en) * | 1994-04-22 | 2000-07-27 | Pentech Pharmaceuticals Inc | SUBLINGUAL DOSAGE FORMS CONTAINING APOMORPHIN FOR USE IN THE TREATMENT OF ERECTILE DYSFUNCTION |
HU218280B (en) * | 1994-04-26 | 2000-07-28 | Cyclodextrin inclusion complexes containing sin-1a which are stable intheir solid state, process for their preparation and pharmaceutical compositions containing the comlexes | |
CA2215307A1 (en) * | 1995-03-14 | 1996-09-19 | Vivus, Incorporated | Pharmaceutical compositions and kits for preventing erectile dysfunction |
GB9511220D0 (en) * | 1995-06-02 | 1995-07-26 | Glaxo Group Ltd | Solid dispersions |
GB9514464D0 (en) * | 1995-07-14 | 1995-09-13 | Glaxo Lab Sa | Medicaments |
US5874437A (en) * | 1996-11-01 | 1999-02-23 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses |
GB9700878D0 (en) * | 1997-01-17 | 1997-03-05 | Scherer Ltd R P | Dosage forms and method for ameliorating male erectile dysfunction |
WO2006104870A2 (en) * | 2005-03-25 | 2006-10-05 | Schering Corporation | Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors |
DE102005016981A1 (en) * | 2005-04-13 | 2006-10-19 | Bayer Healthcare Ag | Combination therapy for benign prostatic hyperplasia |
US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
-
1998
- 1998-09-16 US US09/154,051 patent/US6143746A/en not_active Expired - Lifetime
-
1999
- 1999-08-26 JP JP2000569812A patent/JP2002524516A/en active Pending
- 1999-08-26 WO PCT/US1999/019466 patent/WO2000015228A1/en active Application Filing
- 1999-08-26 EP EP10186240A patent/EP2327408A1/en not_active Withdrawn
- 1999-08-26 BR BR9913824-7A patent/BR9913824A/en not_active Application Discontinuation
- 1999-08-26 CA CA002340636A patent/CA2340636C/en not_active Expired - Fee Related
- 1999-08-26 EP EP99945201A patent/EP1113800A1/en not_active Withdrawn
- 1999-08-26 EP EP08168753A patent/EP2036560A1/en not_active Withdrawn
- 1999-08-26 AU AU57856/99A patent/AU5785699A/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018188446A1 (en) * | 2017-04-14 | 2018-10-18 | 中山大学 | Evodiamine compounds, preparation method therefor and application thereof |
Also Published As
Publication number | Publication date |
---|---|
EP2036560A1 (en) | 2009-03-18 |
BR9913824A (en) | 2001-06-19 |
CA2340636C (en) | 2007-08-07 |
AU5785699A (en) | 2000-04-03 |
EP2327408A1 (en) | 2011-06-01 |
EP1113800A1 (en) | 2001-07-11 |
US6143746A (en) | 2000-11-07 |
WO2000015228A1 (en) | 2000-03-23 |
JP2002524516A (en) | 2002-08-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2340636A1 (en) | Combinations of tetracyclic cyclic gmp-specific phosphodiesterase inhibitors with further therapeutic agents | |
CA2181377A1 (en) | Tetracyclic derivatives, process of preparation and use | |
WO2002064590A3 (en) | Carboline derivatives | |
EA199800907A1 (en) | DERIVATIVES OF CARBOLINE | |
WO2002064591A3 (en) | Carboline derivatives | |
WO2002028865A3 (en) | Condensed pyridoindole derivatives | |
CA2339630A1 (en) | Carboline derivatives as cgmp phosphodiesterase inhibitors | |
AU8816298A (en) | Oxindolylquinazoline derivatives as angiogenesis inhibitors | |
WO2002009715A3 (en) | Use of an arylaldehyde 5-oxo-1, 2, 4-triazine hydrazide for the treatment of cancer | |
IE872615L (en) | TRIAZOLO (1,5-c) PYRIMIDINE DERIVATIVES | |
NZ330973A (en) | Azolobenzazepine derivatives as neurologically active agents | |
WO2002000657A3 (en) | Condensed pyrazindione derivatives | |
AU2001244192A1 (en) | Use of pyrido(3,2-E)-pyrazinones as inhibitors of phosphodiesterase 5 for treating erectile dysfunction | |
PT102457A (en) | PHARMACEUTICAL COMPOSITION CONTAINING A SELECTIVE INHIBITOR OF PDE5 | |
CA2445625A1 (en) | Pyrazino'1',2':1,6!pyrido'3,4-b!indole1,4-dione derivatives | |
MXPA03002914A (en) | Hexahydropyrazino `1 2 : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction. | |
AR002238A1 (en) | DERIVATIVES OF SUBSTITUTED TETRACICLIC AZEPINES, A PROCEDURE FOR THEIR PREPARATION, A COMPOSITION CONTAINING THEM, A PROCEDURE FOR THE PREPARATION OF SUCH COMPOSITION AND THE USE OF SUCH COMPOUNDS FOR THE PREPARATION OF A MEDICINAL PRODUCT. | |
EP0462468A3 (en) | 9-amino-2-phenylbicyclo(3.3.1)nonane and 9-amino-2-phenylbicyclo(3.3.1)-non-2-ene and therapeutic agents containing them | |
ZA893343B (en) | 5-aryl-substituted-2,3-dihydro-imidazo(2,2-a)furo(3,2-c)-or-thieno(2,3-c)pyridines | |
UY24312A1 (en) | PROCEDURE FOR PREPARING TETRACYCLIC DERIVATIVES THAT ARE POTENT AND SELECTIVE INHIBITORS OF THE SPECIFIC PHOSPHODIESTERASE OF CYCLIC GUANOSINE 3 ', 5'-MONOPHOSPHATE. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20170828 |